All In Biotech

Drug Trial Radar · NCT00110461

Aripiprazole in Children and Adolescents With Bipolar I Disorder

A Phase III Trial to Test the Safety and Efficacy of Two Doses of Aripiprazole in Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

Last checked: Nov 19, 2026Latest source record: May 21, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

296

Actual

Start

Mar 2005

Primary completion

Feb 2007

Study completion Feb 2007

Sponsor

Sponsor type
Industry
First posted
May 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 10 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.

Conditions

  • Bipolar Disorder

Interventions

  • AripiprazoleDrug

    Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.

  • AripiprazoleDrug

    Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.

  • placeboDrug

    Placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Young Mania Rating Scale (Y-MRS) Total Score at Week 4Time frame: Baseline and Week 4

Locations

53 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution

    Scottsdale, Arizona

  • Local Institution

    Little Rock, Arkansas

  • Local Institution

    National City, California

  • Local Institution

    Orange, California

  • Local Institution

    Pasadena, California

  • Local Institution

    Sacramento, California

  • Local Institution

    San Diego, California

  • Local Institution

    Stanford, California

  • Local Institution

    Washington D.C., District of Columbia

  • Local Institution

    Altamonte Springs, Florida

  • Local Institution

    Hialeah, Florida

  • Local Institution

    Jacksonville, Florida

  • Local Institution

    Miami, Florida

  • Local Institution

    North Miami, Florida

  • Local Institution

    Tampa, Florida

  • Local Institution

    Atlanta, Georgia

  • Local Institution

    Smyrna, Georgia

  • Local Institution

    Boise, Idaho

  • Local Institution

    Chicago, Illinois

  • Local Institution

    Libertyville, Illinois

  • Local Institution

    Indianapolis, Indiana

  • Local Institution

    Kansas City, Kansas

  • Local Institution

    Newton, Kansas

  • Local Institution

    Lexington, Kentucky

  • Local Institution

    Baton Rouge, Louisiana

  • Local Institution

    Lake Charles, Louisiana

  • Local Institution

    Shreveport, Louisiana

  • Local Institution

    Cambridge, Massachusetts

  • Local Institution

    Medford, Massachusetts

  • Local Institution

    Clinton Township, Michigan

  • Local Institution

    Rochester Hills, Michigan

  • Local Institution

    Kansas City, Missouri

  • Local Institution

    St Louis, Missouri

  • Local Institution

    Las Vegas, Nevada

  • Local Institution

    Elmsford, New York

  • Local Institution

    New York, New York

  • Local Institution

    Rochester, New York

  • Local Institution

    Stony Brook, New York

  • Local Institution

    Cincinnati, Ohio

  • Local Institution

    Cleveland, Ohio

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.